Fertility Practice M&A Multiples: 2026

This report reflects guidance from our bankers, in consultation with healthcare M&A transaction databases, independent valuation research, and publicly available sector studies. We hope to provide fertility practice owners and reproductive endocrinologists with a current, data-supported picture of illustrative valuation multiples and deal market conditions as of 2026.

Key Findings:

• Multiples are strong across practice sizes. Expected valuations range from 8x–10x EBITDA for individual practices with floors higher than most physician specialties.
• Structure and ancillary depth create massive value gaps. MSO infrastructure, in-house embryology labs, and PGT capability can create further multiple spread between the smallest and largest practices at the same EBITDA level.
• Consolidation has cooled, but a secondary wave may be coming. Active acquisitions slowed sharply post-2023 as PE sponsors shifted from add-ons to exits. This has been a general theme across healthcare services, especially in physician practice management. A wave of platform-level transactions is expected as PE groups recapitalize platform assets, which may reinvigorate the market.
• Employer benefits and insurance mandates are fueling demand. Many large employers now offer fertility benefits, and many states mandate IVF coverage, adding predictable, recurring patient volume that buyers actively underwrite.
• Physician supply is the market’s biggest constraint. Only ~1,300 board-certified REIs to serve increasing unmet demand make practices with strong provider retention and associate pipelines structurally more valuable.

2026 Fertility Practice M&A Multiples by Practice Profile

Today’s expected EV/EBITDA multiple ranges reflect the market recalibration that followed the consolidation peak of 2021–2023.^1,2,3

Three key findings stand out in 2026:

1. The practice-level multiple floor is high relative to most physician specialties. The 8x–10x range for fertility clinics reflects both the sector’s structural demand and the relative scarcity of high-quality independent practices available for acquisition. By contrast, most specialties with PE consolidation trade lower, with add-on transactions typically commanding 5.0x–8.0x and platform-scale groups commanding 10.0x+.⁴
2. Platform-level multiples remain elevated but have compressed from the peak. Through 2023, major fertility roll-ups sought exits in the mid-teens or higher. The valuation disconnect between platform buyers and sellers is actively narrowing across much of the PPM sector.
3. Ancillary service depth and clinical outcome data are key separators within any tier.²

Valuation Multiples by EBITDA Scale

Scale tends to drive material multiple expansion across PPM, including in the fertility sector. The multiple gap between a sub-$1M EBITDA single-physician practice and a $5M+ regional group can be substantial.

Buyer type tracks closely with scale: practices below $3M in EBITDA tend to attract existing platform roll-up buyers, while those above $5M can attract new PE sponsors.

Key Valuation Drivers and Their Effect on Multiples

The following table illustrates common premium and compression factors in fertility practice transactions, based on buyer underwriting criteria observed in reported deals and advisory research from PitchBook, SovDoc, and sector-specific M&A firms.^1,2,3

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Between 2004 and 2018, the share of U.S. fertility clinics owned by a larger chain grew from 5% to over 20%.²

Fertility M&A Platform Landscape and Deal Activity (2020–2026)

PE-backed consolidation in the fertility sector accelerated sharply between 2020 and 2023, followed by a meaningful moderation as interest rates rose and growth rates normalized. The table below summarizes the platform landscape and current buyer environment.

Intended for educational purposes only, may not include every active platform or buyer.

Three structural observations define the current deal environment:

• The 2021–2023 consolidation wave has given way to a quality-selective market. Only three U.S. fertility clinic acquisitions by networks were reported through mid-2025, compared to a “frenzy of buying” through the end of 2023. The moderation reflects higher debt costs, normalized post-COVID volumes, and PE sponsors preparing for exits rather than add-ons.
• A wave of secondary transactions may be on the horizon. Most major fertility platform PE sponsors are in the latter stages of their fund cycles, creating pent-up secondary deal flow.
• Debt financing multiples have normalized. This reflects a meaningful increase in cost of capital versus 2020–2022 conditions, compressing the achievable equity return for buyers who paid high multiples at the platform level.³

Fertility Market Size and Demand Fundamentals

The structural demand case for fertility services remains intact across all macroeconomic scenarios. The core drivers (delayed parenthood, rising infertility rates, expanding insurance mandates, and growing employer fertility benefits) are secular trends not subject to economic cyclicality.

U.S. and Global Fertility Market Data — 2026^6.7.8.9

Source: Grand View Research (2024); MMCG Invest (2025); WHO (April 2023); SART / CDC; Mercer Survey (2022); Reproductive Biology and Endocrinology / PMC (2025). Intended for educational purposes only.

Three demand-side developments are actively expanding the addressable market for fertility practices through 2030:

1. State insurance mandates are accelerating treatment-seeking behavior. As mandated coverage expands, the volume of insured patients seeking fertility treatment is growing structurally.⁶
2. Employer fertility benefits have become an increasingly standard competitive offering. With an increasing number of large U.S. employers now providing fertility benefit plans and many covering IVF specifically, employer-contracted volume now represents a material and growing share of clinic patient pipelines, a dynamic that adds predictability and reduces acquisition cost per patient for well-positioned practices.⁶
3. Reproductive endocrinologist supply is the binding constraint on market growth. With approximately 1,300 board-certified REIs serving a patient base of 12.2 million affected Americans, the physician supply-demand imbalance creates a durable structural premium for practices with strong provider retention, associate pipelines, and automated embryology infrastructure.^6,10

Connect with FOCUS Bankers

FOCUS Investment Banking specializes in maximizing transaction value for medical practice owners through our proven quarterback approach to M&A advisory. If you would like to learn more about our healthcare investment banking services or discuss how current market conditions affect the value of your practice, you can reach out to Eric Yetter or Andy Snyder.

Sources

1. PitchBook. Fertility service clinic valuation data. As cited in Objective Investment Banking and Valuation, “M&A in Fertility Outpatient Care Centers Remains Strong.” 2019. objectiveibv.com.
2. SovDoc. How to Value Your Fertility and IVF Practice in a Consolidating Market. June 2025. sovdoc.com.
3. 9fin. Reproductive Services Are Fertile Ground for Private Credit Opportunities. June 2025. 9fin.com.

1. FOCUS Investment Banking, based on internal deal experience and proprietary transaction analysis, 2026.

1. Grand View Research. Fertility Services Market Size and Share Report, 2024–2030. grandviewresearch.com.
2. MMCG Invest. Fertility Clinics Outlook: U.S. Market Analysis Through 2030. 2025. mmcginvest.com.
3. Fertility Bridge / Inside Reproductive Health. The Fertility Sector’s Year in Review: 2025. fertilitybridge.com.
4. World Health Organization. Infertility Prevalence Estimates. April 2023. who.int.
5. Precedence Research. Fertility Market Size to Surpass USD 92.60 Billion by 2035. 2025. precedenceresearch.com.
6. Abraham Zadeh A. Private Equity and Reproductive Medicine: “Fertile Breeding Ground.” Reproductive Biology and Endocrinology. August 2025. pmc.ncbi.nlm.nih.gov.
7. Harris Williams. Fertility Market Overview. harriswilliams.com.
8. Society for Assisted Reproductive Technology (SART). National Summary Report. sartcorsonline.com.